WaveMan
WaveMan · Company
ORKA · Oruka Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ORKA Oruka Therapeutics (ORKA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0000907654
Quote by TradingView
Form 144 · 7
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
195
13F, latest reported quarter
Conversions, 180 days
37
Codes C/M, not in net · $3.4M priced

What the filings say about ORKA

Insiders, 180 days
-$335.6M net sold
7 sellers · 38% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$19.7M
7 notices

Oruka Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Oruka Therapeutics, Inc. insiders sold a net $335.6M of stock across 127 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Quinlan Paul T
General Counsel
SELL
2026-10-20 SEC
400
$30.0K
+0.3%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Sep 21, 2026.
  • The trade is 1.0% of the 38,595 shares held after it.
  • 3 other insiders sold within 30 days.
  • 195 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Quinlan Paul T sold about $30.0K of ORKA under a 10b5-1 plan on Oct 20, 2026; 3 other insiders sold within 30 days and 195 funds added in the latest 13F quarter.
Quinlan Paul T
General Counsel
SELL
2026-10-20 SEC
500
$38.1K
+0.3%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Sep 21, 2026.
  • The trade is 1.3% of the 38,095 shares held after it.
  • 3 other insiders sold within 30 days.
  • 195 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Quinlan Paul T sold about $38.1K of ORKA under a 10b5-1 plan on Oct 20, 2026; 3 other insiders sold within 30 days and 195 funds added in the latest 13F quarter.
Quinlan Paul T
General Counsel
SELL
2026-10-20 SEC
1,000
$77.2K
+0.3%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Sep 21, 2026.
  • The trade is 2.7% of the 37,095 shares held after it.
  • 3 other insiders sold within 30 days.
  • 195 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Quinlan Paul T sold about $77.2K of ORKA under a 10b5-1 plan on Oct 20, 2026; 3 other insiders sold within 30 days and 195 funds added in the latest 13F quarter.
Quinlan Paul T
General Counsel
SELL
2026-10-20 SEC
4,100
$323.0K
+0.3%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Sep 21, 2026.
  • The trade is 12.4% of the 32,995 shares held after it.
  • 3 other insiders sold within 30 days.
  • 195 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Quinlan Paul T sold about $323.0K of ORKA under a 10b5-1 plan on Oct 20, 2026; 3 other insiders sold within 30 days and 195 funds added in the latest 13F quarter.
Quinlan Paul T
General Counsel
SELL
2026-10-20 SEC
3,000
$238.5K
+0.3%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Sep 21, 2026.
  • The trade is 10.0% of the 29,995 shares held after it.
  • 3 other insiders sold within 30 days.
  • 195 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Quinlan Paul T sold about $238.5K of ORKA under a 10b5-1 plan on Oct 20, 2026; 3 other insiders sold within 30 days and 195 funds added in the latest 13F quarter.
127 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 122 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$335.6M over 180 days
-$22.0M over 90 days · -$300.0M of it by a 10%+ holder
below 99% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
195 funds bought in last quarter
more than 90% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
13.7% of the float short (float per yahoo 2026-10-26) · 6.3 days to cover · settled 2026-09-30
more than 77% of Pharma & Biotech
What changed in the last 30 days
Oct 15Officer JOANA GONCALVES filed to sell $1.6M by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 13Officer Arjun Agarwal filed to sell $821.0K by Oct 12 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 13Senior Vice President, Finance Agarwal Arjun sold $805.9K under a 10b5-1 plan (Oct 12)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 2Chief Executive Officer Klein Lawrence Otto sold $2.1M under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 1Director LAWRENCE KLEIN filed to sell $2.1M by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch ORKA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+200.8%12M
-2%+107%+216%+324%2025-102025-122026-022026-042026-062026-082026-10 2026-07-01 · Fairmount Funds Management LLC sold $300.0M2026-09-01 · Klein Lawrence Otto sold $5.8M2026-05-21 · Dambkowski Carl sold $3.2M2026-05-21 · Dambkowski Carl sold $2.2M2026-08-14 · Quinlan Paul T sold $1.6M2026-06-11 · Dambkowski Carl sold $1.6M2026-10-01 · Klein Lawrence Otto sold $1.4M2026-08-14 · Quinlan Paul T sold $1.1M2026-08-14 · Quinlan Paul T sold $1.1M2026-08-14 · Quinlan Paul T sold $1.0M2026-06-12 · Dambkowski Carl sold $882.2K2026-05-21 · Dambkowski Carl sold $793.7K2026-10-01 · Klein Lawrence Otto sold $718.8K2026-09-01 · Klein Lawrence Otto sold $599.6K2026-07-13 · Agarwal Arjun sold $480.2K2026-10-12 · Agarwal Arjun sold $459.5K2026-09-01 · Klein Lawrence Otto sold $443.7K2026-08-14 · Quinlan Paul T sold $427.5K2026-08-14 · Quinlan Paul T sold $385.0K2026-09-11 · Agarwal Arjun sold $374.4K2026-08-17 · Goncalves Joana sold $371.9K2026-09-01 · Sandler Laura Lee sold $368.1K2026-09-21 · Quinlan Paul T sold $357.6K2026-06-15 · Goncalves Joana sold $351.5K2026-07-15 · Goncalves Joana sold $329.6K2026-10-20 · Quinlan Paul T sold $323.0K2026-07-13 · Agarwal Arjun sold $315.4K2026-06-12 · Agarwal Arjun sold $303.1K2026-05-15 · Goncalves Joana sold $295.5K2026-09-15 · Goncalves Joana sold $289.9K2026-08-17 · Goncalves Joana sold $279.2K2026-04-15 · Goncalves Joana sold $277.8K2026-09-11 · Agarwal Arjun sold $273.3K2026-05-18 · Agarwal Arjun sold $272.3K2026-09-21 · Quinlan Paul T sold $267.9K2026-08-13 · Agarwal Arjun sold $255.8K2026-09-21 · Quinlan Paul T sold $254.2K2026-01-02 · Sandler Laura Lee sold $246.4K2026-05-18 · Agarwal Arjun sold $244.4K2026-10-20 · Quinlan Paul T sold $238.5K2026-09-15 · Klein Lawrence Otto sold $234.7K2026-08-13 · Agarwal Arjun sold $230.7K2026-10-15 · JOANA GONCALVES filed to sell $1.6M2026-10-13 · Arjun Agarwal filed to sell $821.0K2026-10-01 · LAWRENCE KLEIN filed to sell $2.1M2026-09-21 · Arjun Agarwal filed to sell $50.6K2026-09-01 · LAWRENCE KLEIN filed to sell $6.9M2026-09-01 · LAURA SANDLER filed to sell $463.1K2026-08-14 · PAUL QUINLAN filed to sell $7.7M2026-07-15 · JOANA GONCALVES filed to sell $1.8M2026-07-13 · Arjun Agarwal filed to sell $2.5M2026-07-01 · Fairmount Healthcare Fund II L.P. filed to sell $300.0M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ORKA: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
9,057,645 sh
$862.0M
BlackRock, Inc.
4,990,181 sh
$474.9M
Venrock Adviser, LLC
4,148,428 sh
$394.8M
Fairmount Funds Management LLC
3,705,262 sh
$352.6M
Capital World Investors
3,401,639 sh
$323.7M

Congress trades in ORKA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ORKA planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
JOANA GONCALVES
Filed 2026-10-15
$1.6M
Arjun Agarwal
Filed 2026-10-13
$821.0K
LAWRENCE KLEIN
Filed 2026-10-01
$2.1M
Arjun Agarwal
Filed 2026-09-21
$50.6K
LAWRENCE KLEIN
Filed 2026-09-01
$6.9M

ORKA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Advisor Biotechnology Fund
$71.2M position · as of 2026-07-31
3.2%
Invesco Dorsey Wright Healthcare Momentum ETF
$6.4M position · as of 2026-07-31
2.7%
Nomura Healthcare Fund
$18.1M position · as of 2026-06-30
2.4%
Franklin Biotechnology Discovery Fund
$21.5M position · as of 2026-07-31
1.9%
ALPS Medical Breakthroughs ETF
$2.9M position · as of 2026-05-31
1.8%
Tactical Allocation Fund (formerly, the Tactical Growth Allocation Fund)
$625.6K position · as of 2026-06-30
1.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 5 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
0 active
5
Phase 2
5 active
What changed recently
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
2026-10-17 · Recruiting → Active Not Recruiting
Phase 2
ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Sing
2026-10-10 · Active Not Recruiting → Completed
Phase 1
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
2026-09-01 · Not Yet Recruiting → Recruiting
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$358.8K
$523.8K
$382.7K
-41%
n/a
2021
$526.5K
$409.9K
$393.3K
-46%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $335.6M sold by insiders over 180 days, 195 funds added last quarter, $19.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ORKA financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2023-07-01 to 2024-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$101.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-18.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-17.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-21.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-1.9%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/an/a$0$0
Operating income-$122.1Mn/a-$7.3M-$10.6M
Net income-$105.4M-$83.7M-$5.3M-$9.9M
EPS (diluted)n/an/a-0.37-0.69
Operating cash flow-$88.2Mn/a-$5.0M-$10.9M
Cash$46.9M$61.6M$37.4M$42.4M
SEC XBRL, fiscal years, as known on 2026-10-27

ORKA Stock Sonar score 4/7 axes

Find similar shapesCompare

ORKA ranks highest on institutional and government (90th percentile) and profitability (71st), and lowest on insider conviction (1st), among Pharma & Biotech peers.

Profitability
71
Inputs
  • Return on equity-18.2% · 73 pct, sector of 545
  • Return on assets-17.8% · 69 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-21.2% · 72 pct, sector of 576
Insider conviction
0
Inputs
  • Net Form 4 buying (codes P and S), 180d-$321.4M · 1 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
90
Inputs
  • Funds adding, latest quarter195 · 90 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
27
Inputs
  • Short interest, % of float+13.7% · 28 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+16.2% · 26 pct, sector of 511
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ORKA filings, in plain words

Are Oruka Therapeutics insiders buying or selling ORKA?

In the 180 days to 2026-10-27, Oruka Therapeutics insiders were net sellers, a net $335.6M across purchases and sales reported on Form 4, by 7 sellers.

Are there planned insider sales of ORKA?

Yes. 7 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $19.7M of stock; the latest, by JOANA GONCALVES, was filed 2026-10-15.

Read the full summary

In the 180 days to 2026-10-27, Oruka Therapeutics insiders were net sellers of ORKA, a net $335.6M across purchases and sales reported on Form 4 by 7 sellers. Most of that figure, $300.0M, came from a holder of 10% or more rather than an officer or director. 38% of the 98 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 7 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $19.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies